Contributions
Abstract: PB2383
Type: Publication Only
Background
Historically, few FDA approved treatments for multiple myeloma (MM) were available, with bortezomib and lenalidomide considered the standard of care. Recently, several new treatments for MM have been approved by FDA. With only a short time on the market, little is known about how the new MM treatments are being utilized in routine clinical practice and how the standard of care may be evolving.
Aims
To address this gap in understanding, this real-world study described the characteristics of patients initiating a new line of therapy (LOT) and characteristics of the new LOTs.
Methods
This retrospective study utilized data from IBM Explorys Research Database to identify MM patients with no record of stem cell transplant and ≥1 record for MM treatment between 11/2015 - 9/2017 (study period). An algorithm was used to identify new LOTs based on MM therapies (excluding corticosteroids) initiated during the study period. Descriptive analyses characterized utilization of all MM therapies and combinations.
Results
A total of 2615 patients started a new LOT during the study period. 1753 (67.0%) patients who started a new LOT were ≥65 years and 1169 (44.7%) were female. 1629 (62.3%) patients started 1st LOT, 426 (16.3%) started 2nd LOT, 235 (9.0%) started 3rd LOT, and 325 (12.4%) started 4th or more LOT. Among the new LOTs, the most common regimens were lenalidomide (n = 733 (28.0%)), bortezomib (n = 463 (17.7%)), bortezomib+lenalidomide (n = 345 (13.2%)), daratumumab (n = 219 (8.4%)), and bortezomib+cyclophosphamide (n = 187 (7.2%)). Less common regimens included pomalidomide (n = 75 (2.8%)) and carfilzomib (n = 44 (1.7%)).
Conclusion
This real-world study suggests that the MM treatment paradigm is evolving to include newer therapies, however, bortezomib and lenalidomide remain common regimens. As disease recurrence is often more aggressive and survival shorter with each subsequent LOT, critical research is in progress to understand the real-world effectiveness of new treatments and how use in earlier LOTs vs. later LOTs may impact effectiveness.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Multiple Myeloma
Abstract: PB2383
Type: Publication Only
Background
Historically, few FDA approved treatments for multiple myeloma (MM) were available, with bortezomib and lenalidomide considered the standard of care. Recently, several new treatments for MM have been approved by FDA. With only a short time on the market, little is known about how the new MM treatments are being utilized in routine clinical practice and how the standard of care may be evolving.
Aims
To address this gap in understanding, this real-world study described the characteristics of patients initiating a new line of therapy (LOT) and characteristics of the new LOTs.
Methods
This retrospective study utilized data from IBM Explorys Research Database to identify MM patients with no record of stem cell transplant and ≥1 record for MM treatment between 11/2015 - 9/2017 (study period). An algorithm was used to identify new LOTs based on MM therapies (excluding corticosteroids) initiated during the study period. Descriptive analyses characterized utilization of all MM therapies and combinations.
Results
A total of 2615 patients started a new LOT during the study period. 1753 (67.0%) patients who started a new LOT were ≥65 years and 1169 (44.7%) were female. 1629 (62.3%) patients started 1st LOT, 426 (16.3%) started 2nd LOT, 235 (9.0%) started 3rd LOT, and 325 (12.4%) started 4th or more LOT. Among the new LOTs, the most common regimens were lenalidomide (n = 733 (28.0%)), bortezomib (n = 463 (17.7%)), bortezomib+lenalidomide (n = 345 (13.2%)), daratumumab (n = 219 (8.4%)), and bortezomib+cyclophosphamide (n = 187 (7.2%)). Less common regimens included pomalidomide (n = 75 (2.8%)) and carfilzomib (n = 44 (1.7%)).
Conclusion
This real-world study suggests that the MM treatment paradigm is evolving to include newer therapies, however, bortezomib and lenalidomide remain common regimens. As disease recurrence is often more aggressive and survival shorter with each subsequent LOT, critical research is in progress to understand the real-world effectiveness of new treatments and how use in earlier LOTs vs. later LOTs may impact effectiveness.
Session topic: 36. Quality of life, palliative care, ethics and health economics
Keyword(s): Multiple Myeloma